This company listing is no longer active
Amryt Pharma Crecimiento futuro
Future controles de criterios 5/6
Información clave
53.9%
Tasa de crecimiento de los beneficios
50.8%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 20.7% |
Tasa de crecimiento de los ingresos | 26.3% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 12 Apr 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2025 | 595 | 153 | N/A | N/A | 1 |
12/31/2024 | 428 | 141 | N/A | N/A | 2 |
12/31/2023 | 325 | -3 | 59 | N/A | 4 |
12/31/2022 | 266 | -64 | 34 | N/A | 4 |
9/30/2022 | 244 | -1 | 107 | 108 | N/A |
6/30/2022 | 239 | 3 | -32 | -30 | N/A |
3/31/2022 | 233 | 3 | 4 | 5 | N/A |
12/31/2021 | 223 | 1 | 14 | 16 | N/A |
9/30/2021 | 210 | -88 | -89 | -86 | N/A |
6/30/2021 | 203 | -81 | 46 | 50 | N/A |
3/31/2021 | 186 | -92 | 21 | 23 | N/A |
12/31/2020 | 183 | -105 | 24 | 27 | N/A |
9/30/2020 | 180 | -87 | 5 | 6 | N/A |
6/30/2020 | 140 | -92 | -18 | -17 | N/A |
3/31/2020 | 98 | -87 | -26 | -26 | N/A |
12/31/2019 | 58 | -63 | -38 | -37 | N/A |
12/31/2018 | 17 | -30 | -16 | -15 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: 3N9A is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Beneficios vs. Mercado: 3N9A is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: 3N9A is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: 3N9A's revenue (26.3% per year) is forecast to grow faster than the German market (3.2% per year).
Ingresos de alto crecimiento: 3N9A's revenue (26.3% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 3N9A's Return on Equity is forecast to be high in 3 years time